Selexis CHO Cells in Suspension-1

Archives 2017

Selexis has been setting the pace of innovation in protein expression and establishing new benchmarks in bioproduction for  two decades.

DECEMBER 20, 2017
3 min read

Selexis SA and Turgut Pharmaceuticals Advance Partnership with Third Commercial License Agreement

Supports Advancement of Biosimilar to Treat Two Ultra-Rare Diseases

Geneva, Switzerland, and Istanbul, Turkey, 20...

Read More
OCTOBER 4, 2017
4 min read

Selexis SA and Pelican Therapeutics Sign Agreement to Advance Pelican’s Immunotherapy Clinical Programs

Selexis to Develop High-performance Research Cell Banks to Expedite the Manufacturing of Immunotherapy Clinical...

Read More
SEPTEMBER 26, 2017
5 min read

Selexis SA and OSE Immunotherapeutics Expand Strategic Alliance to Further Advance OSE’s OSE-172 and OSE-703 Cancer Immunotherapy Programs

Second and Third Commercial License Agreements Between the Partners Underscore the Advantages of Selexis’...

Read More
SEPTEMBER 20, 2017
4 min read

Selexis SA, Spinomix SA and the University of Lausanne Publish Novel, High-Throughput Technology Process for Isolation of High Secretion CHO Cell Clones

Paper in Biotechnology and Bioengineering describes faster and more efficient technology for isolation of...

Read More
SEPTEMBER 5, 2017
2 min read

Selexis to Participate at Several Upcoming Industry Conferences

Geneva, Switzerland, 5 SEPTEMBER 2017Selexis SA, a pioneering life sciences company and a global leader in mammalian...

Read More
JUNE 27, 2017
2 min read

Selexis Announces Commercial License Agreement with Takeda for the Development of Fusion Proteins

Geneva, Switzerland, 27 June 2017Selexis SA, a pioneering life sciences company and a global leader in mammalian...

Read More
JUNE 14, 2017
4 min read

JSR Life Sciences Agrees to Acquire Pioneering Cell Line Developer Selexis SA and Integrate Selexis with KBI Biopharma, Inc.

JSR Life Sciences, the life-sciences focused division of JSR Corporation, will offer industry partners best-in-class...

Read More
JUNE 12, 2017
3 min read

Selexis SA and TeneoBio, Inc. Team Up to Advance the Development of UniAbs Targeting Cancer

Geneva, Switzerland and Menlo Park, CA, 12 JUNE 2017Selexis SA and TeneoBio, Inc. announced today that they have...

Read More
MAY 30, 2017
2 min read

Merck KGaA, Darmstadt, Germany Licenses Selexis SUREtechnology Platform for Immuno-Oncology Antibody Program

Geneva, Switzerland, 30 MAY 2017Selexis SA, a pioneering life sciences company and a global leader in mammalian cell...

Read More
MAY 23, 2017
5 min read

Selexis SA and OSE Immunotherapeutics Sign Commercial License Agreement to Further Advance Development of OSE’s Interleukin Receptor 7 Antagonist

Geneva, Switzerland, and Nantes, France, 23 May 2017 – Selexis SA and OSE Immunotherapeutics SA (ISIN: FR0012127173;...

Read More
MAY 11, 2017
3 min read

Selexis SA Opens New World-Class Laboratory Facility and Corporate Headquarters in Geneva, Switzerland

Geneva, Switzerland, 12 May 2017 – Selexis SA, a pioneering life sciences company and a global leader in mammalian...

Read More
MARCH 20, 2017
2 min read

Selexis Announces Launch of Novel Cell Selection Platform Designed to Help Advance Difficult-to-Express Protein Therapeutics to the Clinic

SUREselect can improve the quality of clone selection for cell lines used to manufacture protein therapeutics and...

Read More
MARCH 14, 2017
2 min read

Selexis Announces Participation at Several Upcoming Industry Conferences

Geneva, Switzerland, 14 MARCH 2017Selexis SA, a pioneering life sciences company and a global leader in mammalian...

Read More
FEBRUARY 21, 2017
2 min read

Selexis to Develop Cell Lines for Three Sanofi Biologics Programs Using Selexis SUREtechnology Platform™

Selexis SA Inks Agreement for Applications in Cancer and Infectious Disease Selexis to develop cell lines for three...

Read More